IMUX down 42% - nice bounce from opening price (I missed that) - Phase 2 study of vidofludimus calcium, its lead asset, missed the primary endpoint in patients with moderate-to-severe ulcerative colitis
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.